Currently, the standard management strategy for diabetic kidney disease (DKD) mainly includes strict blood glucose and blood pressure control and management of the renin-angiotensin system (RAS) blockade; however, the efficacy and safety of RAS blockade therapy remain controversial (Suissa et al., 2006; Sarafidis and Bakris, 2009). The gene discussed is REN; the disease is diabetic kidney disease.